
    
      Children participating in this study will either receive RTS,S/AS02D (0.5 ml dose) or
      RTS,S/AS02A (0.25 ml dose) intramuscularly according to 0, 1, 2 months schedule. The children
      will be followed-up throughout the study period to record safety events. Blood samples will
      be collected at defined time points to assess the subject's immune response to the relevant
      immunological indicators.
    
  